Related Experiment Video

Updated: May 26, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Drug resistance in glioblastoma: a mini review

Catherine P Haar1, Preetha Hebbar, Gerald C Wallace

  • 1Divisions of Neurology and Neurosurgery, Department of Neurosciences, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA.

Neurochemical Research
|January 10, 2012
PubMed

Insights

Glioblastoma multiforme (GBM) drug resistance is a major challenge. This review details mechanisms like drug efflux, hypoxia, and stem cells, highlighting plant-derived agents as potential therapies.

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor.
  • Current treatments offer limited survival benefits due to inherent complexity and drug resistance.
  • Understanding resistance mechanisms is crucial for developing effective therapies.

Purpose of the Study:

  • To review the primary mechanisms of drug resistance in glioblastoma.
  • To explore potential therapeutic strategies targeting these resistance pathways.
  • To highlight the role of plant-derived agents in overcoming glioblastoma drug resistance.

Main Methods:

  • Comprehensive literature review of published English-language studies on glioblastoma drug resistance.
  • Identification and summarization of key resistance mechanisms.
  • Analysis of emerging therapeutic approaches, including plant-derived agents.

Main Results:

  • Key glioblastoma drug resistance mechanisms identified: drug efflux pumps, tumor hypoxia, cancer stem cells, DNA damage repair, and microRNAs (miRNAs).
  • Various therapeutic strategies targeting these mechanisms are under investigation.
  • Plant-derived agents show promise as alternative or complementary treatments.

Conclusions:

  • Drug resistance significantly limits glioblastoma treatment efficacy.
  • Targeting specific resistance mechanisms, potentially through combination therapies, is essential.
  • Further investigation into plant-derived therapeutics is warranted for glioblastoma treatment.

More Related Videos

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...